Indefinite Delivery Contract SPE2DU25D5137

The federal contract IDV award SPE2DU25D5137 was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,999,999.00 contract, effective August 1, 2025 through December 31, 2036, is an Indefinite Delivery Contract that enables the DLA to procure a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract serves as a prime vehicle for the DLA to efficiently obtain essential medical commodities for the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The original solicitation for this IDV, known as the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), is an unrestricted, fully competitive acquisition by the DLA Troop Support Medical Supply Chain. The $30.3 billion contract will establish multiple regional primary supplier awards, as well as a separate backup supplier, to ensure resiliency and access to vital pharmaceuticals during contingencies or natural disasters. Contractors will be selected based on the lowest overall distribution fees for brand/generic and specialty drugs to support normal operations and contingencies CONUS and OCONUS.